The interest in PBP4 is unusual because it acts on the same cellular construction system targeted by major classes of antibiotics without itself being an essential target. In S. aureus, peptidoglycan is assembled from repeating N-acetylglucosamine and N-acetylmuramic acid units whose stem peptides are crosslinked to strengthen the bacterial cell wall. High-molecular-weight penicillin-binding proteins, or PBPs, perform much of this work. PBP1 supports cell division, PBP2 participates in septal peptidoglycan synthesis, and PBP3 contributes to peripheral cell-wall construction. By contrast, PBP4 is a class C low-molecular-weight enzyme that can crosslink preassembled peptidoglycan and exchange noncanonical D-amino acids at peptide termini. Deleting pbp4 reduces peptidoglycan crosslinking and makes bacterial cells more elastic, consistent with a role in repairing or modifying the wall after initial construction.

Biochemical findings provide evidence that PBP4 directly transpeptidizes peptidoglycan. Purified protein can incorporate D-amino acids into muropeptides even when abundant water is present, a property expected of a transpeptidase rather than a carboxypeptidase. Its sequence contains the SXXK, SXN and KTG motifs characteristic of PBP active sites. Serine 75 is thought to attack the D-Ala-D-Ala terminus of a stem peptide and form an acyl-enzyme intermediate, after which an adjacent peptide or its pentaglycine bridge can become the acceptor. Wild-type cells incorporate fluorescent noncanonical D-amino acids into their walls, whereas pbp4 deletion sharply reduces this activity. Some findings nevertheless leave open the possibility that PBP4 also recruits other enzymes, particularly PBP2, to support crosslinking in intact cells. The proposed catalytic sequence remains largely inferred from sequence conservation, structural analogy and in vitro results rather than established through a full mechanistic analysis.

PBP4 has also emerged in studies of a resistance phenotype that does not depend on the conventional mecA gene. mecA encodes PBP2A, an extra transpeptidase that lets S. aureus continue crosslinking peptidoglycan when the native PBP2 is inhibited by beta-lactams. In a stepwise selection experiment, researchers exposed a mecA-deficient strain to increasing ceftobiprole concentrations. The resulting mutant resisted ceftobiprole, ceftaroline and other beta-lactams without producing PBP2A. It carried a 36-base-pair duplication upstream of pbp4 and two amino-acid substitutions near the enzyme’s predicted active site. Moving the promoter duplication into the parent strain increased PBP4 production 20- to 40-fold and produced a resistant phenotype, while the PBP4 substitutions alone did not do so. These observations associate elevated PBP4 activity with resistance but do not fully establish the molecular mechanism. Possible explanations include altered transpeptidase activity, changes in peptidoglycan remodeling, or sequestration of beta-lactams.

Clinical-isolate studies support the relevance of this route to resistance. Deleting pbp4 produced 16-fold reductions in oxacillin and nafcillin resistance in community-acquired MRSA strains, although the deletion did not have the same effect in the hospital-acquired strains examined. In another survey of 185 mecA-independent MRSA clinical isolates, 8 carried pbp4 mutations, 22 carried gdpP mutations, and 155 carried mutations in both regulatory or coding regions associated with the two genes. Moving pbp4-related mutations into a susceptible background increased resistance to nafcillin, oxacillin and ceftaroline, and combining them with loss of gdpP produced high-level resistance in the reported experiments. The molecular basis for that synergy remains unresolved. A separate structural study found PBP4-mediated hydrolysis of ampicillin and cefotaxime, but whether PBP4 acts as a beta-lactamase during infection is unknown. Together, these findings suggest that mecA-based testing may underestimate the prevalence of beta-lactam-resistant S. aureus.

A second disease-related function involves osteomyelitis, a bone infection that is difficult to eradicate because bacteria can occupy osteocyte lacuno-canalicular networks, or OLCNs. These interconnected channels are roughly 100 to 600 nanometres wide within mineralized bone, whereas a staphylococcal cell is about one micrometre across, meaning the bacterium must deform to enter. Scanning electron microscopy has shown that S. aureus colonizes OLCNs in chronically infected mouse bone and in samples from diabetic patients. Within these spaces, bacteria are shielded from host defenses and antibiotics, creating a plausible reservoir for reinfection. A transposon screen found that pbp4 disruption prevented OLCN invasion in a laboratory canalicular model and in animals. Atomic-force-microscopy studies indicate that PBP4 contributes to cell-wall stiffness, which may help bacteria withstand confinement and maintain wall integrity, although the molecular mechanism connecting PBP4 activity to invasion has not been established.

That link between wall mechanics and invasion suggests a possible dual function for a PBP4 inhibitor. One application would be to weaken a resistance mechanism and restore the activity of beta-lactams such as ceftobiprole or ceftaroline, which inhibit PBP2A and have been used against MRSA. Another would be to prevent bacteria from entering bone channels before establishing a protected reservoir. The review proposes using such a drug as an adjuvant rather than as a stand-alone antibiotic, including during prophylaxis or treatment for severe open tibial fractures. This setting has a relatively high osteomyelitis incidence: a retrospective study of 235 patients with type III open diaphyseal tibial fractures found 16.6% developed osteomyelitis. By contrast, infection following total joint replacement is reported in only 1% to 2% of patients, creating a much larger obstacle to demonstrating a preventive effect. The proposed strategy remains preclinical and has not been tested as a clinical intervention.

Early chemical studies offer support for the concept without establishing a therapy. A high-throughput screen identified six compound classes that reduced or eliminated beta-lactam resistance in cells overexpressing a PBP4 variant. The compounds did not reduce bacterial viability in laboratory culture, bound PBP4 more selectively than other PBPs, and inhibited fluorescent D-alanine incorporation into peptidoglycan and OLCN invasion in vitro. Phenyl urea and benzothiophene inhibitors received particular attention, and structure-guided analogues showed stronger activity than the parent compounds. Some analogues also reversed PBP2A-mediated resistance, indicating that compounds initially considered PBP4-selective may inhibit additional PBPs. Their selectivity therefore requires careful evaluation before therapeutic effects could be attributed specifically to PBP4. These results concern cell-based assays and in vitro invasion models; they do not establish reduced infection, improved outcomes or safety in patients.

Cefoxitin has served as an informative probe because it has greater affinity for PBP4 than for other S. aureus PBPs. At sub-antimicrobial concentrations, it restored beta-lactam susceptibility in PBP4-associated resistant strains and reversed serum-associated daptomycin tolerance linked to cell-wall thickening. Cefoxitin is unsuitable as an ideal selective PBP4 drug, however: it is not orally available, requires frequent intravenous dosing and carries risks including nephrotoxicity, disruption of gut microbiota and selection of resistance. More selective non-antimicrobial inhibitors might avoid some of these liabilities, but targeting a protein that becomes important during resistance or pathogenesis can itself create evolutionary pressure. Reduced drug binding, efflux, altered permeability and other bypass mutations remain plausible routes of resistance and must be assessed experimentally for each compound. The review also notes that the expectation of less resistance to inhibitors of non-essential targets cannot be assumed and should be tested target by target.

The review concludes that PBP4 deserves continued investigation as an antimicrobial target because it links a noncanonical resistance phenotype with bacterial invasion of protected bone niches, potentially allowing one class of compounds to address two clinical problems. Its 99.07% amino-acid sequence identity across surveyed S. aureus genomes suggests that a shared inhibitor might be possible across lineages, while related PBP4 changes in Enterococcus faecalis and Pseudomonas aeruginosa indicate broader relevance. Nevertheless, no PBP4 inhibitor has yet demonstrated safety or efficacy in humans. The immediate path is to clarify the enzyme’s resistance mechanism, optimize compounds for true PBP4 selectivity, test whether resistance emerges, and evaluate adjuvants in populations with a sufficiently high osteomyelitis event rate. Until those steps are completed, PBP4 remains an emerging target with mechanistic promise rather than an established treatment strategy.

Subject of Research: Preclinical development of PBP4 inhibitors for antibiotic resistance and staphylococcal osteomyelitis

Article Title: Penicillin binding protein 4: an emerging Staphylococcus aureus therapeutic target

Article References: Gondil, V. S., Stefaniak, M. A., Melander, C., & Dunman, P. M. (2026). Penicillin binding protein 4: an emerging Staphylococcus aureus therapeutic target. Frontiers in Cellular and Infection Microbiology, 16, 1940058. https://doi.org/10.3389/fcimb.2026.1940058

Image Credits: AI Generated

DOI: 10.3389/fcimb.2026.1940058

Keywords: Staphylococcus aureus, penicillin-binding protein 4, PBP4 inhibitors, antibiotic resistance, MRSA, beta-lactams, osteomyelitis, peptidoglycan, ceftaroline, ceftobiprole, Penicillin, binding

The clinical burden underlying this research direction is substantial. Osteomyelitis, the infection of bone marrow and surrounding bone tissue addressed in the review, is driven most often by Gram-positive staphylococci, with Staphylococcus aureus alone implicated in roughly 44% to 75% of cases and particularly dominant in chronic presentations. Once established, these infections resist conventional treatment not simply because the bacteria themselves are hardy, but because they organize into biofilms—structured communities that adhere to implant surfaces, necrotic bone fragments, and other hospitable niches. Within these communities, bacteria are shielded from both innate and adaptive immune responses and display markedly reduced susceptibility to antimicrobial drugs. The result is a vicious cycle in which surgical debridement and prolonged antibiotic courses frequently fail to eradicate the infection, leaving many patients to progress to chronic disease marked by inflammation-driven bone destruction, heightened osteoclast activity, and secondary osteonecrosis.

The piezoelectric principle at the heart of the proposed strategy rests on a deceptively simple physical property. Materials with non-centrosymmetric crystal lattices—meaning their internal structure lacks a center of symmetry—develop separated positive and negative charge centers when mechanically deformed. This deformation generates electric dipoles and, on the material surface, localized bound charges. The phenomenon runs in both directions: the direct piezoelectric effect converts applied mechanical force into electrical charge, while the inverse effect converts an applied electric field into mechanical deformation. For biomedical purposes, the direct effect is the more relevant one, since it allows the body’s own mechanical environment—walking, loading, ultrasound applied from outside, even subtle internal tissue movements—to be harvested as a source of localized electrical stimulation without any external power supply implanted at the site.

What makes this particularly attractive for infected bone is the multiplicity of antibacterial mechanisms that can flow from that single physical event. When a piezoelectric surface is mechanically stimulated, the resulting charge separation can, in catalytically active systems, drive redox reactions that generate reactive oxygen species. These highly reactive molecules damage bacterial membranes, interfere with intracellular redox balance and respiratory processes, and attack the extracellular polymeric matrix that gives biofilms their structural integrity. Importantly, the review emphasizes that reactive oxygen species are not the whole story. Electrical perturbation at the material surface, direct mechanical disruption of biofilm architecture, interfacial electron transfer, and the release of metal ions can each contribute to bacterial killing and biofilm dismantling. This mechanistic plurality matters clinically, because a therapy that attacks bacteria through several parallel pathways is inherently less vulnerable to the resistance mechanisms that defeat single-target antibiotics.

The review’s authors argue that the field has tended to organize itself around material classifications, antibacterial mechanisms, or application categories, and that this taxonomy has obscured something clinically essential: bone infection is not a static problem but a dynamic pathological sequence. Persistent biofilms, dysregulated antimicrobial immunity, excessive or unresolved inflammation, and impaired angiogenesis and osteogenesis are not independent events. They are interconnected processes that unfold in a characteristic order as infection is controlled and repair proceeds. A material that aggressively generates reactive oxygen species may be ideal in the first days after debridement, when bacterial load and biofilm burden are highest, yet counterproductive weeks later, when the priority shifts to protecting nascent blood vessels and differentiating osteoblasts from oxidative damage.

To resolve this tension, the authors propose a stage-adaptive therapeutic framework. In the early infection-control phase, the priorities are biofilm disruption, bacterial eradication, and activation of antimicrobial immune functions. Piezoelectrically generated electrical signals and reactive oxygen species serve these goals directly, while the same stimuli can polarize immune cells toward a microbicidal phenotype that complements the materials’ direct antibacterial action. Once the infectious burden has been sufficiently reduced, the therapeutic emphasis must pivot: oxidative stress must now be contained, persistent inflammation resolved, and the immune microenvironment remodeled toward a pro-reparative state that supports angiogenesis—the sprouting of new blood vessels that supply regenerating tissue—followed by osteogenesis, the deposition of new bone matrix.

This reframing has practical consequences for material design. Rather than seeking a single material that maximizes every desirable property simultaneously, the framework suggests that next-generation implants might be engineered to modulate their own behavior over time, for example by tuning piezoelectric output, incorporating catalytic components whose activity is triggered by the local microenvironment, or layering coatings that release pro-regenerative signals only after the acute phase has passed. The review also situates piezoelectric materials within a broader lineage of biomedical applications; these substances already serve as nanogenerators in soft tissue repair and underpin technologies from medical ultrasound transducers to aerospace actuators and radio-frequency filters in consumer electronics, reflecting decades of industrial maturation that could accelerate clinical translation.

The immune dimension of the framework deserves particular attention, because it connects the antibacterial and regenerative phases into a coherent narrative. The review synthesizes evidence that piezoelectric stimulation can modulate the infection-associated immune microenvironment, steering the inflammatory response in ways that support both bacterial clearance and subsequent repair. This is a subtle balancing act. The same inflammatory programs that mobilize bactericidal activity early in infection can, if left unresolved, drive the bone destruction and fibrosis that characterize chronic osteomyelitis. A material platform that first amplifies antimicrobial immunity and then facilitates its resolution—without requiring drug interventions at each transition—would address one of the most persistent failures of current therapy, in which dysregulated host responses perpetuate disease even after bacteria have been substantially cleared.

The authors are candid about the obstacles that remain between this framework and routine clinical use. Material design optimization is an ongoing challenge: piezoelectric coefficients, biocompatibility, degradation behavior, and mechanical properties must be balanced within a single implantable system, and the optimal parameters likely differ between the infection-control and repair phases. Mechanistic understanding also remains incomplete. While the individual pathways—piezocatalytic reactive oxygen generation, electrical stimulation of cells, immune modulation—have each been demonstrated, their relative contributions in vivo, their interactions with one another, and their dependence on the local mechanical loading environment are not yet fully mapped. Clinical translation faces the additional hurdle that most supporting evidence comes from in vitro and preclinical models, which rarely reproduce the complexity of human osteomyelitis with its mixed bacterial populations, devitalized bone, and compromised vascularity.

Nevertheless, the conceptual contribution of the review lies in its insistence that therapeutic functions be evaluated against the pathophysiological timeline of the disease rather than in isolation. By integrating antibacterial action, immunomodulation, and regeneration into a single stage-adaptive sequence, it offers researchers a design logic: identify which phase of the disease a given material property serves, and engineer materials whose properties evolve in step with the patient’s needs. If that logic can be validated experimentally and carried through to clinical devices, piezoelectric biomaterials could shift the treatment of infected bone from a reactive cycle of debridement and antibiotics toward an active, self-regulating partnership between implant and host tissue—one in which the mechanical energy of everyday movement becomes a therapeutic resource deployed precisely when and where the healing process requires it.

Subject of Research: Piezoelectric biomaterials for treating bone infection through bacterial eradication, immune modulation, and bone regeneration

Article Title: Immunomodulation and biofilm disruption of piezoelectric materials in bone infection

Article References: Wang, Z., Zheng, K., Tang, Y., Zhang, Z., Zhong, Z., Wang, D., Chen, Z., Wang, Y., Chen, Z., Feng, P., Huang, W., Liu, M., Hao, Y., Yu, F., Wang, G., Yi, M., & Deng, X. (2026). Immunomodulation and biofilm disruption of piezoelectric materials in bone infection. Frontiers in Cell and Developmental Biology, 14, Article 1976300. https://doi.org/10.3389/fcell.2026.1976300

Image Credits: AI Generated

DOI: 10.3389/fcell.2026.1976300

Keywords: piezoelectric materials, bone infection, biofilm, osteomyelitis, reactive oxygen species, immunomodulation, bone regeneration, antibacterial biomaterials, disruption, piezoelectric, materials, bone

The team began by screening 210 non-duplicate clinical specimens, from which they recovered 120 Staphylococcus aureus isolates. Identification relied on classical microbiology, including Gram staining, catalase and coagulase testing, and mannitol fermentation, followed by molecular confirmation through PCR amplification of the 16S rRNA gene and enterotoxin genes. Methicillin resistance was determined by Kirby-Bauer disk diffusion according to Clinical and Laboratory Standards Institute guidelines, with an oxacillin inhibition zone smaller than 10 millimeters indicating resistance, and was confirmed genetically by amplification of the mecA gene. Seventeen isolates, or 14.16 percent, proved to be MRSA, while the remaining 103 were methicillin-sensitive.

To find viruses capable of killing these resistant bacteria, the researchers turned to the environment. They sampled pond water from sites around Varanasi, river water from the Ganga and Yamuna rivers and the Sangam confluence at Prayagraj, and sewage from both a municipal treatment plant and the drainage of a university hospital. Using the double agar overlay plaque assay, they isolated 47 bacteriophages, designated φRAGS1 through φRAGS47. Hospital sewage was by far the richest source, yielding 39 of the isolates, a reflection of the dense bacterial populations that phages and their hosts exchange in such environments.

When the phages were typed against the clinical isolates, six of them, φRAGS1, φRAGS8, φRAGS15, φRAGS21, φRAGS37 and φRAGS47, showed broad host-range lytic activity against MRSA strains at titers of 10¹² plaque-forming units per milliliter. Dendrogram analysis of the sensitivity profiles sorted the full collection into sixteen cluster groups. Transmission electron microscopy then revealed the architecture of the six lead phages: two, φRAGS8 and φRAGS37, carry an icosahedral head with a short, non-contractile tail, placing them in the Podoviridae-like morphotype, while four, φRAGS1, φRAGS15, φRAGS21 and φRAGS47, possess long contractile tails characteristic of the Myoviridae-like group, classified according to International Committee on Taxonomy of Viruses criteria.

Molecular characterization reinforced the morphological split. Restriction digestion of purified phage DNA with the hexa-cutter enzymes EcoRI and HindIII produced distinct fragment patterns consistent with two separate viral families, and low-melting-temperature ERIC-PCR fingerprinting, performed after three sequential plaque passages, confirmed that the genomes remained stable across propagation cycles. Notably, a polar plot of lytic activity showed that φRAGS15 lysed all 17 clinical MRSA strains, marking it as the strongest single candidate for future development, while φRAGS21 showed comparatively weaker activity across the panel.

The second pillar of the strategy is the implant material itself. The researchers worked with carbonate-intercalated Mg²⁺/Al³⁺ layered double hydroxide nanoparticles, known as nanoLDH, incorporated at 1 percent by weight into poly(methyl methacrylate) bone cement, the standard acrylic grouting material used in hip and knee replacements since its FDA approval in 1969. The resulting nanocomposite was characterized by X-ray diffraction, scanning and transmission electron microscopy, ultraviolet-visible spectroscopy, Fourier transform infrared spectroscopy and thermogravimetric analysis. Previous work by the group had already shown through hemolysis, thrombogenicity, simulated body fluid apatite formation and osteoblast cell culture assays that the nanohybrid cement is more biocompatible than conventional PMMA and supports bone-forming activity.

To test the therapy, 24 female rabbits received prostheses implanted into a drilled defect in the distal femoral metaphysis under ketamine and midazolam anesthesia. The animals were divided into a control group, a group receiving conventional bone cement, and a nanoLDH group that was further split into an implant-only subgroup and an implant-plus-phage subgroup. Six days after surgery, an MRSA inoculum of 5 × 10⁶ colony-forming units was injected intramedullary to establish infection, which was verified by culture, susceptibility testing and mecA amplification. Once infection was confirmed, rabbits in the phage group received subcutaneous injections of a lyophilized six-phage master mix, at 10¹² PFU/mL and a dose of 15 microliters per kilogram, into the soft tissue surrounding the implant on days 12, 15 and 18.

The outcome data showed a clear therapeutic gradient across the groups. Untreated infected rabbits and those with conventional cement developed progressive cortical erosion, and the cement group additionally showed osteolysis, reactive sclerosis and sequestrum formation, the hallmarks of chronic implant-associated osteomyelitis. Rabbits with nanoLDH alone fared better, with reduced osteolysis and early new bone formation, but the most dramatic improvement appeared in the phage-treated nanoLDH group: radiographs on day 18 revealed substantial restoration of cortical architecture, marked new bone around the implant and no progression of sequestra, while cultures from the implant site turned negative after treatment. Histopathology mirrored these findings, with near-complete disappearance of inflammatory infiltrates, minimal necrosis, woven bone bridging cortical defects and restored marrow architecture in the phage-treated animals, compared with dense neutrophilic infiltration, abscesses and extensive necrosis in the cement group.

Recovery timelines underscored the magnitude of the effect. Animals receiving the nanoLDH-phage combination recovered in about 18 days, roughly half the 36-day recovery observed in untreated controls, with nanoLDH alone at 24 days and conventional cement at 30 days. Statistical analysis using the non-parametric Kruskal-Wallis test followed by Dunn’s multiple comparison test with Bonferroni correction confirmed significant differences among all groups. The authors are careful to note the limits of their claims: they did not directly demonstrate sustained phage release from the cement or definitively prove a mechanistic synergy between the nanomaterial and the viruses, and the phages were delivered by subcutaneous injection at the implant site rather than embedded in the prosthesis itself.

Even with those caveats, the study adds a technically detailed data point to the growing field of phage therapy for orthopedic infections, where staphylococcal species account for roughly four out of five prosthetic joint infections and two-thirds of cases involve S. aureus. Because phages recognize specific bacterial surface receptors and replicate at the site of infection, they offer strain-specific killing that antibiotics such as vancomycin, linezolid and daptomycin, each increasingly hampered by resistance and side effects, cannot match. The researchers suggest that future work should compare phage-loaded prostheses directly against conventional antibiotic therapy and standalone phage treatment, and pursue whole-genome sequencing to confirm the absence of undesirable genes in the φRAGS isolates. If those steps succeed, locally delivered phage cocktails paired with osteoconductive nanohybrid cements could become a credible alternative to antibiotic-loaded bone cement for managing multidrug-resistant implant infections.

Subject of Research: Bacteriophage therapy combined with nanohybrid bone cement for treating MRSA prosthetic joint infections

Article Title: Synergistic application of φRAGS bacteriophages and nanohybrid bone cement-based joint prostheses against methicillin-resistant Staphylococcus aureus

Article References: Mishra, R. R., Mishra, P., Kishor, C., Kumar, A., Kumar, A., & Nath, G. (2026). Synergistic application of φRAGS bacteriophages and nanohybrid bone cement-based joint prostheses against methicillin-resistant Staphylococcus aureus. Frontiers in Virology, 6, Article 1880302. https://doi.org/10.3389/fviro.2026.1880302

Image Credits: AI Generated

DOI: 10.3389/fviro.2026.1880302

Keywords: bacteriophage therapy, MRSA, prosthetic joint infection, bone cement, nanoLDH, Staphylococcus aureus, antimicrobial resistance, PMMA, rabbit model, osteomyelitis, φRAGS phages, biomaterials

The research team, led by investigators at Rutgers School of Public Health and Columbia University, focused on four of the most serious bacterial infections associated with injection drug use: skin and soft tissue infections, osteomyelitis, infective endocarditis, and central nervous system abscesses. These conditions represent a spectrum of severity, from painful tissue infections that may require surgical drainage to life-threatening heart valve infections and brain abscesses that demand weeks of intravenous antibiotics. All of them share a common thread in the context of the ongoing drug overdose crisis, in which contaminated injection practices introduce bacteria into the bloodstream and deep tissues, creating infections that frequently require prolonged hospitalization.

Methodologically, the study is a retrospective cohort analysis designed to produce nationally representative estimates. The researchers applied survey weights to the Nationwide Readmission Database, a federal dataset that captures readmissions across state lines and allows analysts to track patients who move between hospitals, a critical feature given that many patients with substance use disorders receive care at multiple institutions. After weighting, the analysis encompassed 392,984 index admissions of adults hospitalized with a primary diagnosis of one of the four target infections. Each admission was classified into one of four exposure groups based on ICD-10-CM diagnostic codes: neither disorder, opioid use disorder only, stimulant use disorder only, or co-occurring opioid and stimulant use disorders.

The demographic profile of the cohort underscores how deeply these infections intersect with an aging population of people who inject drugs. The mean age of hospitalized patients was 58.8 years, 57.1 percent were male, and 46.9 percent carried Medicare coverage, a striking figure for a population often assumed to be younger and uninsured. Within the cohort, 4.5 percent of admissions involved opioid use disorder alone, 3.9 percent involved stimulant use disorder alone, and 2.4 percent involved both disorders simultaneously. The overall unplanned readmission rates were 4.3 percent within seven days of discharge and 12.48 percent within thirty days, meaning roughly one in eight patients returned to the hospital within a month of being sent home.

After statistical adjustment for patient and hospital characteristics, the central finding emerged clearly: having opioid use disorder, stimulant use disorder, or both was associated with higher odds of both seven-day and thirty-day unplanned all-cause readmission compared with patients who had neither disorder. This pattern held across the short and slightly longer follow-up windows, suggesting that the elevated risk is not confined to the immediate post-discharge period but persists through the first month, when patients are typically transitioning from intravenous antibiotics in the hospital to oral regimens or outpatient infusion therapy.

Perhaps the most clinically provocative result concerns the co-occurring group. Patients diagnosed with both opioid and stimulant use disorders showed higher odds of readmission than those with opioid use disorder alone, although the authors note that this particular comparison did not reach statistical significance in their models. The direction of the effect is nonetheless consistent with a growing body of literature on polysubstance use, which suggests that people who use multiple drug classes experience compounded medical and social vulnerabilities. Stimulants such as methamphetamine and cocaine can drive frequent injection episodes, cardiovascular strain, and erratic engagement with care, while opioids contribute to overdose risk and withdrawal-related treatment disruption. When both disorders are present, the pathways back to the hospital may multiply.

The mechanisms behind these associations are likely multifactorial, and the study’s design cannot fully disentangle them. Patients with untreated opioid use disorder may leave the hospital against medical advice to avoid withdrawal, cutting short antibiotic courses for infections like endocarditis that require weeks of therapy. Others may be discharged without linkage to medications for opioid use disorder such as buprenorphine or methadone, returning to injection practices that seed new infections at old or new sites. Social factors, including housing instability, lack of transportation to follow-up appointments, and stigma within healthcare settings, can compound the pharmacological challenges. Readmissions in this population may also reflect non-infectious causes, including withdrawal, overdose, and complications of untreated chronic disease, since the study measured all-cause readmission rather than infection-specific recurrence.

For the authors, the implications point squarely toward integrating addiction treatment into inpatient infection care. Hospitalization for a serious bacterial infection represents a rare moment of sustained contact between this population and the healthcare system, often the longest period of stability a patient experiences in months. Evidence from other fields suggests that initiating medications for opioid use disorder during hospital admission, combined with warm handoffs to community-based treatment, can reduce subsequent opioid use and improve retention in care. The new findings extend the logic to infectious diseases practice, where hospitals have historically treated the infection and discharged the patient without addressing the underlying substance use disorder that produced it.

The study carries important caveats that shape how its results should be interpreted. Diagnostic codes for substance use disorders depend on clinician documentation, and undercoding is common, particularly for stimulant use disorder, which may mean some exposed patients were misclassified as unexposed and the true associations could be stronger than estimated. The all-cause readmission outcome cannot distinguish between returns driven by infection relapse and those driven by other acute events. As with any database study, residual confounding by severity of illness, social determinants of health, and treatment intensity remains possible. The authors also relied on the 2022 database year, and patterns of drug use and hospital practice continue to evolve rapidly, meaning the estimates represent a snapshot of a dynamic epidemic.

Even with those limitations, the scale of the analysis gives its central message considerable weight. Nearly 400,000 weighted hospitalizations for injection-related bacterial infections in a single year, with one in eight patients readmitted within thirty days, describes an enormous and largely preventable burden on patients, families, and the healthcare system. The finding that opioid and stimulant use disorders independently elevate short-term readmission risk reframes these disorders not as peripheral social issues but as central clinical drivers of infectious disease outcomes. As the authors conclude, embedding addiction medicine within inpatient infectious disease care, from bedside initiation of treatment to structured post-discharge linkage, could transform the hospital stay from a revolving door into a genuine turning point for one of the most vulnerable populations in American medicine.

Subject of Research: The association between opioid and stimulant use disorders and unplanned hospital readmission after injection drug use-related bacterial infections

Article Title: The impact of co-occurring opioid and stimulant use disorders on unplanned readmissions among patients hospitalized with bacterial infections

Article References: Hu, J., Blair, N., Mauro, P. M., Samples, H., Bushnell, G., Yin, M. T., & Shiau, S. (2026). The impact of co-occurring opioid and stimulant use disorders on unplanned readmissions among patients hospitalized with bacterial infections. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14321-3

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14321-3

Keywords: opioid use disorder, stimulant use disorder, bacterial infection, hospital readmission, injection drug use, infective endocarditis, osteomyelitis, polysubstance use, addiction treatment, Nationwide Readmission Database, infectious diseases, public health

The study, led by Badrul Akmal Hisham Md Yusoff and colleagues in the Department of Orthopedics and Traumatology, was conducted as a prospective cohort trial running from April 2024 to December 2025. Sixteen patients fitted with external fixators were enrolled and divided into two groups according to their consent to treatment: ten patients received Hydrocyn gel as their dressing agent, while six received conventional flavin-based dressing. Both groups performed self-dressing every three days, an important design feature because it tested whether the gel could perform under real-world conditions in which patients, not clinicians, manage their own pin sites at home. Patients were then followed weekly for four weeks, with any infection diagnosed and graded using the Checkettts-Otterburn scale, a widely used clinical classification that ranges from mild cellulitis to severe infection requiring pin removal.

The results, while preliminary, were striking. In the Hydrocyn gel group, only two of the ten patients developed a pin-site infection, a rate of 20 percent. In the flavin group, four of six patients became infected, a rate of 66.7 percent. The pattern of infections also differed between the groups. Patients treated with Hydrocyn gel developed only Grade 1 infections, the mildest category on the Checkettts-Otterburn scale. One of these resolved spontaneously without intervention, while the other worsened and required surgical debridement and removal of the affected pin. In the flavin group, by contrast, infections appeared earlier and more frequently, with one patient requiring early debridement and multiple cases progressing to Grade 2 and Grade 3 severity. Encouragingly, no patient in either group developed osteomyelitis, the feared deep bone infection that can follow untreated pin-site sepsis.

To understand why a superoxidized gel might hold an advantage, it helps to examine the chemistry. Hydrocyn gel belongs to a family of agents based on stabilized superoxidized solutions, or SOS, which contain reactive oxygen species such as hypochlorous acid suspended in a hydrogel matrix. These reactive species attack microbial cells through multiple pathways simultaneously, oxidizing cell membranes, denaturing proteins, and disrupting biofilms, the sticky bacterial communities that are notoriously resistant to conventional antiseptics and antibiotics. The gel formulation offers an additional practical benefit: it maintains prolonged contact with the wound surface, keeping the antimicrobial agent in place between dressing changes, whereas liquid antiseptics can drain away or evaporate within hours of application.

The conventional comparator in the study, flavin-based dressing, represents the historical standard of pin-site care. Flavins are photosensitizing dyes with antimicrobial properties that have been used in wound management for generations, and they remain common in many orthopedic centers around the world. However, their mechanism of action is narrower, and concerns about cytotoxicity to human cells and limited activity against biofilm-embedded bacteria have prompted surgeons to search for alternatives. The Malaysian team’s hypothesis was that a broad-spectrum, reactive-oxygen-based agent with sustained contact time could suppress bacterial colonization more effectively at the vulnerable pin-skin interface.

The Checkettts-Otterburn grading system deserves particular attention because it transforms infection from a binary event into a spectrum of clinical severity. Grade 1 infections involve mild pin-tract redness that responds to simple measures, while higher grades indicate increasing inflammation, discharge, and loosening of the pin, with the most severe grades requiring surgical intervention and raising the specter of osteomyelitis. By grading infections rather than merely counting them, the researchers could show not only that fewer Hydrocyn gel patients became infected, but that the infections that did occur were less severe on average. This distinction matters clinically, because the burden of pin-site infection lies less in the occasional mild irritation and more in the progression to deep infection that can compromise fracture treatment entirely.

Despite the encouraging numbers, the authors are careful to frame their findings as hypothesis-generating rather than proof of efficacy. The study was a pilot, and several methodological limitations temper any strong conclusions. Most importantly, treatment allocation was based on patient consent rather than randomization, meaning that patients who chose the gel may have differed systematically from those who chose flavin dressing in ways that influenced infection risk. The sample size of sixteen patients is far too small to exclude the role of chance, and because the trial was registered retrospectively, on 2 March 2026, after data collection had begun, no inferential statistical tests were performed at all. The reported rates of 20 percent and 66.7 percent are therefore descriptive observations, not statistically compared estimates, and the true difference between the two treatments could be smaller or larger than what was observed.

These limitations are not trivial, but they are also not unusual for early-stage surgical research. Pilot studies of this kind serve a specific purpose in the clinical development pipeline: they generate preliminary effect sizes, test the feasibility of recruitment and follow-up, and identify practical challenges before larger randomized trials are attempted. The fact that patients in both groups successfully performed self-dressing every three days and completed weekly follow-up for four weeks suggests that a definitive trial is logistically feasible. The authors’ decision to report descriptive results honestly, without dressing them in statistical significance they cannot support, reflects a commendable commitment to scientific transparency in a field where small studies are often oversold.

The broader context of pin-site infection makes the search for better dressings clinically urgent. External fixators are indispensable in trauma surgery, particularly for open fractures, limb reconstruction, and the correction of deformities, and the duration of fixation can extend for months. Every week that pins remain in place is another week of exposure to bacterial colonization, and infection rates reported across the literature vary enormously, in part because there has never been agreement on the best cleaning regimen, dressing material, or frequency of care. This lack of consensus means that patients in different hospitals, and even different wards within the same hospital, may receive entirely different pin-site care based on local tradition rather than evidence. A rigorous trial demonstrating superiority of one agent over another would have immediate practical value for thousands of patients worldwide.

For now, the message from Kuala Lumpur is one of cautious optimism. Hydrocyn gel, with its reactive oxygen species and sustained-release hydrogel format, was associated with a lower observed rate of pin-site infection and a milder pattern of disease than conventional flavin dressing in this small trauma population, and no patient in either group developed the deep bone infection that surgeons dread most. Whether that association survives the scrutiny of a properly randomized, adequately powered trial remains to be seen, but the pilot provides exactly the kind of preliminary signal that such a trial needs. If future studies confirm the trend, a simple change in dressing material, applied by patients themselves at home, could meaningfully reduce one of the most common and troublesome complications of modern fracture care.

Subject of Research: Pin-site infection prevention in external fixation using a superoxidized hydrogel dressing compared with flavin-based care

Article Title: A prospective pilot cohort study of hydrocyn gel as a dressing agent compared with conventional flavin-based pin-site care for infection prevention

Article References: Md Yusoff, B. A. H., Jasmin, L. N. A., Nik Kamaruzman, N. K. A., Mohamad, N., Ramlan, M. K. R., & Azwan Aziz, M. (2026). A prospective pilot cohort study of hydrocyn gel as a dressing agent compared with conventional flavin-based pin-site care for infection prevention. Scientific Reports. https://doi.org/10.1038/s41598-026-75590-1

Image Credits: AI Generated

DOI: 10.1038/s41598-026-75590-1

Keywords: external fixator, pin-site infection, Hydrocyn gel, superoxidized solution, flavin dressing, Checkettts-Otterburn scale, orthopedic trauma, wound care, antimicrobial hydrogel, biofilms, osteomyelitis, pilot cohort study

The work, published in the Journal of Bone and Joint Infection, was coordinated through the African Bone and Joint Infection Network under the auspices of the European Bone and Joint Infection Society, with support from the AO Alliance. Led by Loïc Fonkoué of Yaoundé General Hospital in Cameroon and Elizabeth Tissingh of King’s College London, the group spanned 14 countries, from Ethiopia and Malawi to Switzerland and the United Kingdom. Every member had direct experience treating bone and joint infections in resource-limited environments, a deliberate design choice meant to ensure the recommendations reflect clinical reality rather than idealized conditions.

The recommendations were built through a three-step process. First, two 34-item questionnaires were distributed to network members in November 2024, gathering responses from 86 clinicians in 22 countries about their current practice and their most urgent needs. Second, a one-day consensus meeting was held during the annual congress of the College of Surgeons of East Central and Southern Africa in Harare, Zimbabwe, in December 2024, where a draft document was agreed upon. Third, the wider panel conducted an iterative collaborative review from December 2024 to February 2025, revising recommendations until broad agreement was reached. Notably, the group did not use formal voting or evidence grading, acknowledging that the evidence base from low-income settings is too thin for such methods.

A central technical point of the guidance is terminology and diagnosis. The experts endorse the term fracture-related infection, or FRI, which supersedes older labels such as post-traumatic osteomyelitis and fracture-fixation-associated infection. Because it is impossible to reliably distinguish deep from superficial infection after a fracture, any surgical-site infection following a fracture is considered an FRI. Diagnosis should rest primarily on clinical criteria: sinus tracts, purulence, wound breakdown, and delayed or failed bone healing all warrant suspicion. This emphasis matters because late presentation is common in low-resource settings, and by the time patients arrive, the classic confirmatory signs are often the only reliable indicators available.

The guidelines are equally pragmatic about laboratory and imaging resources. Wound swabs and sinus tract samples are explicitly discouraged for microbiological culture, since they tend to grow skin commensals that do not represent the true pathogen. Instead, intra-operative tissue sampling is the diagnostic test of choice: five samples taken with separate clean instruments raise diagnostic yield to 97 percent, compared with 84 percent for three samples, though three samples are deemed acceptable under constraint. Routine X-rays should be prioritized over costly CT, MRI, or nuclear imaging, which are helpful but not essential. Histology offers a low-cost adjunct, with more than five neutrophils per high-power field considered significant, a technique accessible even in laboratories that mainly process malaria blood films.

Perhaps the most striking technical content concerns antibiotic strategy. Data from Cameroon and Nigeria show that Gram-negative bacteria account for 65.8 percent and 49 percent of fracture-related infections respectively, a markedly different profile from high-income countries where Staphylococcus aureus dominates. The experts therefore recommend empirical therapy combining a glycopeptide, such as vancomycin, with an agent active against Gram-negatives, such as amikacin or meropenem, with cefazolin plus gentamicin as a fallback. For definitive oral therapy, they favor bactericidal drugs with high oral bioavailability and good bone penetration, including rifampicin, fluoroquinolones, clindamycin, and fosfomycin, while cautioning against cephalosporins for oral use and against the rifampicin-clindamycin combination, which risks inducible resistance.

Local antibiotic delivery receives detailed attention because it demonstrably works: in a study of 433 confirmed infections, adding local antibiotics to definitive management cut failure rates from 18.3 percent to 10.3 percent. Polymethylmethacrylate cement, readily available and affordable across Africa, can be fashioned into spacers or beads, though it requires removal surgery and has poorer drug elution than absorbable calcium sulfate and composite ceramic carriers. The guidelines also flag a practical dilemma: rifampicin, the cornerstone of anti-biofilm therapy for implant retention, is often restricted to tuberculosis treatment programs in African countries. Encouragingly, evidence from the SOLARIO trial suggests that when local antibiotic carriers are used, as little as seven days of systemic therapy may suffice, a finding with major implications for adherence and antimicrobial stewardship.

On the surgical side, the recommendations preserve the universal principles of meticulous debridement of dead tissue until punctate bleeding appears, copious low-pressure saline irrigation without additives, and rigid fracture stabilization. But they also codify resource-adapted innovations. Where patients cannot afford a new implant, the group endorses debridement and implant sterilization, in which the removed hardware is re-sterilized and reused during the same operation. Debridement and implant retention is favored for early infections when fixation is stable, since implants are scarce. For dead-space management, options range from the induced-membrane Masquelet technique with cement to antibiotic-impregnated bone autografts and bone transport using external frames. The group also warns against prolonged vacuum-assisted dressings, citing evidence that negative pressure wound therapy more than doubles recurrence risk in fracture-related infection.

Prevention and system-level reform round out the guidance. Improved early management of open fractures, which can become infected in up to 52 percent of cases in some series, is identified as the single most effective strategy for reducing the disease burden, alongside WHO surgical safety checklists, engagement with community leaders and traditional bone setters to reduce treatment delays, and optimization of comorbidities including HIV, diabetes, anemia, and malnutrition. The recommendations have been packaged as the seventh ACTIONS guideline, part of the African Consensus for Trauma in Orthopaedics: National Standards series, and are available in English, French, and Portuguese to maximize uptake across the continent.

The authors are candid about the limitations: much of the guidance rests on expert consensus rather than trials conducted in the settings it targets, and urgent research priorities include building treatment networks, defining optimal antibiotic regimens and sampling protocols, and establishing supply chains for local antibiotic carriers and circular fixators. They call on ministries of health, clinicians, and industry to invest in training, reconstructive capacity, and diagnostics. The guidelines do not replace international standards, the authors stress; rather, they translate essential principles into feasible strategies for the hospitals where the burden of bone infection is greatest, while insisting that robust audit and locally generated evidence will be needed to refine them for the future.

Subject of Research: Consensus guidelines for managing fracture-related infection in low-resource settings in Africa

Article Title: Management of fracture-related infection in low-resource settings in Africa: recommendations and guidelines from an international expert group

Article References: Fonkoué, L., Tissingh, E. K., Marais, L. C., Malaba, M., Abrha, K., Ferguson, J., Morgenstern, M., Cornu, O., Laubscher, M., Buzisa Mbuku, R., Galiwango, G. W., Botman, M., Wojno, J., Majigo, M. V., Martin Jr., C., Harrison, W. J., Schade, A. T., Marenah, K., Nyamutora, M., … McNally, M. (2026). Management of fracture-related infection in low-resource settings in Africa: recommendations and guidelines from an international expert group. Journal of Bone and Joint Infection, 11(4), 401-411. https://doi.org/10.5194/jbji-11-401-2026

Image Credits: AI Generated

DOI: 10.5194/jbji-11-401-2026

Keywords: fracture-related infection, osteomyelitis, low-resource settings, Africa, orthopaedic surgery, antibiotic stewardship, consensus guidelines, global health, surgical infection, open fractures, microbiology, AO Alliance

The work, published in the Journal of Bone and Joint Infection, addresses a stubborn gap in orthopedic research. Implant-associated bone infections are among the most feared complications of joint replacement and fracture fixation, often forcing revision surgery, prolonging morbidity, and driving up costs. Staphylococcus aureus, the culprit in the new study, is particularly troublesome because it adheres readily to biomaterial surfaces and establishes persistent biofilms. Although antibacterial coatings and antibiotic-releasing materials are advancing rapidly, their clinical translation depends on preclinical models that faithfully reproduce the conditions under which infections take hold. Existing animal models vary enormously in implant design, bacterial strain, inoculation route, dose, and timing, making it difficult to compare results across laboratories or to know whether a coating that works in one construct will work in another.

The Utrecht-led team designed a demanding but clinically relevant construct. Adult male Wistar rats, twelve weeks old and skeletally mature, received a six-millimeter segmental defect in the mid-shaft of the femur, created with a saw guide and wire saw. A three-dimensional-printed porous titanium implant was press-fit into the gap, and the whole construct was stabilized with a polyether-ether-ketone, or PEEK, plate fixed by six screws. This is not a simple intramedullary pin or transcortical screw model. The segmental defect creates a large implant-tissue interface, a structured porous scaffold surface, and a complex mechanical environment that mirrors the settings where infection risk is highest clinically: tumor resection, severe trauma, and revision surgery. The porous titanium was chosen deliberately, because its open-pore geometry resembles that of load-bearing porous implants used in real bone reconstruction and provides an ideal substrate for future testing of antibacterial coatings.

Three experiments, involving twenty-eight animals in total, of which twenty-five entered the final analysis, mapped the infection landscape across two time points. In the early model, planktonic S. aureus, a clinical isolate originally obtained from a patient with chronic osteomyelitis, was inoculated directly onto the implant surface at the moment of surgery, at either ten thousand or one million colony-forming units per rat. In the delayed model, the same doses were delivered twenty-eight days after implantation, injected percutaneously into the implant site. A third experiment escalated the delayed challenge to one hundred million colony-forming units, delivered either as free-swimming planktonic bacteria or as a ruptured-biofilm inoculum, in which biofilms grown in the laboratory were scraped from culture wells and dispersed by sonication. Fourteen days after each inoculation, the animals were euthanized and bacterial burdens were quantified in homogenized bone and in sonicated implants, plates, and screws, with micro-computed tomography confirming hardware positioning and implant integrity.

The results were strikingly asymmetric. In the early setting, both doses produced consistent infections across every sampled compartment. Bones carried bacterial loads of roughly one hundred thousand to one million colony-forming units, implants were colonized at around one thousand to ten thousand units, and plates and screws harbored about one hundred thousand units each. Uninfected controls receiving phosphate-buffered saline showed no growth, and the contralateral, unoperated femora remained sterile, confirming that infection stayed localized to the inoculated defect. In the delayed setting, however, the same ten thousand and one million unit doses largely failed. Bone cultures were only sporadically positive, and not a single implant in either delayed group showed detectable colonization, with take rates of zero out of three. The peri-implant environment that had matured over four weeks simply refused entry to bacterial challenges that would have been devastating on the day of surgery.

Escalation changed the picture. When the delayed challenge was raised to one hundred million colony-forming units, delivered by surgically re-exposing the implant, both the planktonic and the ruptured-biofilm groups developed sustained bone infection, with detectable bacteria in every animal. Notably, the ruptured-biofilm inoculum produced higher bacterial burdens on the implant, plate, and screws than the equivalent planktonic dose, while bone burdens were consistently high in both arms. The authors interpret this as evidence that biofilm-derived aggregates carry enhanced infectious potential: the extracellular polymeric substance that shields bacteria from clearance also promotes surface adhesion, and biofilm physiology alters bacterial surface and virulence profiles in ways that favor attachment and immune evasion. Clinically, this matters because although hematogenous seeding often begins with planktonic cells, biofilm fragments shed from distant sites can recolonize implants and sustain chronicity.

Why is a four-week-old implant site so much more resistant? The study’s explanation centers on the maturation of the host-implant interface. At implantation, the surface is unencapsulated, the acute inflammatory response has not yet contained contaminants, and disrupted local defenses strongly favor bacterial adhesion, a dynamic captured by the well-known concept of the race for the surface. By four weeks, wound closure, peri-implant fibrous tissue and callus, and an established local immune milieu create physical and immunological barriers. Only a challenge above a critical threshold, in this case one hundred million colony-forming units, could disturb that equilibrium. Importantly, no animals in the high-dose delayed groups showed signs of systemic illness during the fourteen days after inoculation; body weight losses stayed within two to five percent, and no animal reached the predefined humane endpoints for sepsis, suggesting the infection remained localized rather than spreading.

The authors are candid about the limitations of a feasibility study. Group sizes of three to four animals mean statistical power is low, and the findings should be read as descriptive trends rather than validated reproducibility; formal inferential statistics were deliberately not applied. The one-hundred-million-unit dose required for delayed infection is substantially higher than typical hematogenous bacterial loads, leaving open the question of whether the delayed model best represents late surgical contamination, hematogenous seeding, or a stress test of host defense. Micro-computed tomography was used only qualitatively to confirm hardware position, and infection confirmation relied on microbiological culture without histopathology, so future work should add quantitative bone imaging and tissue-level verification of biofilm architecture. The team also notes that surgical re-exposure in the third experiment, while ensuring accurate inoculum placement, may transiently weaken local barriers compared with percutaneous injection, a potential confounder when comparing across experiments.

Even with those caveats, the model fills a specific and important niche. It allows antibacterial implant coatings to be evaluated under two distinct host-implant maturation states within a single standardized construct, something simpler intramedullary or non-segmental models cannot fully provide. The small pilot cohorts reflect the exploratory, model-establishment nature of the work and align with the principles of replacement, reduction, and refinement that govern ethical animal research. With larger-scale validation, the dual-time-point platform could become a practical proving ground for the next generation of anti-infective implants, tested against both the bacteria that arrive during surgery and the harder-to-defeat challenges that appear weeks later. For the growing population of patients carrying orthopedic hardware, a reliable way to test prevention against both faces of implant infection is a step toward keeping those devices, and the bones around them, safe for good.

Subject of Research: A rat femoral-defect model for studying immediate and delayed implant-associated bone infections

Article Title: Feasibility of a rat femoral-defect model for immediate perioperative and delayed post-implantation implant-associated bone infections

Article References: Keikhosravani, P., Croes, M., Rahmani, N. R., Stabuli, F., Cecotto, L., Vogely, H. C., van der Wal, B. C. H., Koolen, M., Gawlitta, D., Weinans, H., Khodaei, A., & Amin Yavari, S. (2026). Feasibility of a rat femoral-defect model for immediate perioperative and delayed post-implantation implant-associated bone infections. Journal of Bone and Joint Infection, 11(4), 535-546. https://doi.org/10.5194/jbji-11-535-2026

Image Credits: AI Generated

DOI: 10.5194/jbji-11-535-2026

Keywords: implant-associated infection, Staphylococcus aureus, biofilm, rat model, femoral defect, porous titanium, PEEK plate, osteomyelitis, antibacterial coatings, preclinical model, micro-CT, orthopedic surgery

The condition at the heart of the study, infected non-union, is defined by the combination of two failures: the bone has not consolidated for at least six months with no radiographic progress over the preceding three months, and a fracture-related infection has been confirmed according to international consensus criteria. Confirmation requires at least one hard finding, such as a sinus tract communicating with the fracture, purulent drainage, identical microorganisms cultured from at least two deep tissue samples, or histopathological evidence of infection. At surgery, the Marseille team routinely obtained at least five deep tissue specimens, incubating cultures for a minimum of ten days to capture slow-growing organisms. The stakes are high because bacterial biofilms on implants and dead bone shield pathogens from both the immune system and antibiotics, making spontaneous healing essentially impossible without major surgery.

The 22 patients in the cohort illustrate just how refractory these cases can be. Ninety-five percent had post-traumatic infected non-unions, mostly after high-energy road traffic accidents, and 82 percent had originally sustained open fractures, which carry a high risk of contamination. The median patient was 45 years old, and the median interval between the initial trauma and the reconstructive procedure was 14 months, with one patient not reaching reconstruction until more than 15 years after the original injury. Before arriving at the vascularized graft option, patients had undergone a median of four previous operations, and 41 percent had already failed a Masquelet induced-membrane reconstruction, a two-stage technique that coaxes the body to grow a membrane around a cement spacer before bone grafting. These were, in short, patients for whom conventional reconstruction had already run out of road.

Vascularized fibular grafting, first described in the 1970s, takes advantage of the fibula, the slender bone running alongside the tibia, which can be harvested with its feeding vessel, the peroneal artery, and transplanted as free living tissue. In a single operative session, a combined orthopedic and plastic surgery team first performed radical debridement of infected bone and soft tissue, then harvested the graft from the opposite leg in most cases, preserving at least five centimeters of proximal fibula and seven centimeters of distal fibula to protect knee and ankle stability. The graft was inserted into the healthy bone segments bridging the defect, fixed with internal or external hardware, and connected to recipient vessels through microsurgical anastomoses, with the posterior tibial vessels preferred when anatomy allowed. The median bone defect measured 90 millimeters and the median graft 115 millimeters, lengths that exceed what most non-vascularized techniques can reliably bridge.

The biological rationale for this approach is what makes it so appealing in infected fields. Because the transplanted fibula arrives with intact microcirculation, it does not depend on the often scarred and poorly vascularized recipient bed for survival. Living bone maintains its own osteogenic potential, remodels under load, and, crucially, its preserved blood flow may improve local immune defense and the delivery of antibiotics to the infected site, a decisive advantage against biofilm-associated organisms such as Staphylococcus aureus, coagulase-negative staphylococci, Pseudomonas aeruginosa, and, in one case, even Candida albicans. Eighty-two percent of the infections were polymicrobial, and antimicrobial therapy, individualized by infectious-disease specialists according to intraoperative cultures, continued for a median of 22 weeks after surgery. Notably, no patient remained on suppressive antibiotics at final follow-up, suggesting that in successfully treated cases the infection was truly eradicated rather than merely contained.

The headline results are encouraging but come with an important caveat about time. Bone consolidation, defined as radiographic bridging of at least three of four cortices on orthogonal views together with painless full weight-bearing, was achieved in 17 of 22 patients, or 77 percent. Infection remission occurred in 16 patients, and overall treatment success, the combination of both, in 16 patients, or 73 percent. Nine patients healed with the vascularized graft alone, at a median of 14 months, while seven required a secondary bone graft because consolidation was delayed, and their median time to union stretched to 38 months. Strikingly, all seven patients who underwent secondary grafting ultimately achieved union, although the authors caution that because the procedure was performed selectively at varying time points, this observation cannot be interpreted as proof of a causal benefit.

The methodological heart of the paper lies in its competing-risk analysis, a statistical framework that treats amputation and death not as censored observations, as traditional Kaplan-Meier methods do, but as genuine alternative outcomes that permanently preclude consolidation. This distinction matters because Kaplan-Meier curves can overestimate healing rates when patients leave the risk set for reasons other than the event of interest. Using cumulative incidence functions, the team calculated that the probability of consolidation was only about 18 percent at 12 months, rising to 41 percent at 24 months, 59 percent at 36 months, and roughly 76 percent by the end of follow-up. In other words, judging the success of a vascularized fibular graft at the one-year mark dramatically understates what the procedure can eventually deliver, a finding with direct implications for surgeons and patients deciding whether to persist with reconstruction or abandon the limb.

Not every story ended well, and the study is candid about the price of failure. Six patients, 27 percent of the cohort, had unfavorable outcomes: four amputations, one persistent non-union, and one death. The amputations stemmed from distinct pathways, including persistent infection despite early radiographic progress, ongoing pain and major depression in one patient who requested the procedure, and vascular thrombosis compromising the flap in another. Complications were documented on both the recipient and donor sides, including leg length discrepancies in five patients with a maximum of 65 millimeters, lower-limb malformation in two, a fractured fixation plate, graft non-union requiring multiple reoperations, and arteriovenous thrombosis in two patients, one of whom ultimately lost the limb. These numbers underline that vascularized fibular grafting is a technically demanding microsurgical undertaking that requires careful patient selection and multidisciplinary backup.

The authors are appropriately measured about the limits of their evidence. The study was retrospective, single-center, and small, precluding regression analyses to identify predictors of success, and follow-up duration was heterogeneous, with a median observation time of 21.5 months but a range extending to 90 months. Functional outcomes, quality of life, and patient satisfaction were not systematically collected, and donor-site complications may have been underestimated because they were not prospectively recorded. Consolidation rates in the broader literature, which range from 70 to 90 percent in mixed cohorts that include tumor and congenital reconstructions, are not directly comparable to this exclusively infected, multiply-failed population. Still, the central message stands: for selected patients with infected non-union of the femur or tibia, a living bone transplant can save a limb that would otherwise be amputated, but healing is a marathon measured in years, not months, and only long-term follow-up with methods that respect competing risks can reveal the true odds.

Subject of Research: Long-term outcomes of vascularized fibular grafting as limb-salvage surgery for infected non-union of the lower limb

Article Title: Long-term outcomes of vascularized fibular grafting for infected non-union of the lower limb: a competing-risk analysis

Article References: Le Hir, A., Seng, P., Delarbre, D., Ambrosino, R., Kachouh, N., Legré, R., & Stein, A. (2026). Long-term outcomes of vascularized fibular grafting for infected non-union of the lower limb: a competing-risk analysis. Journal of Bone and Joint Infection, 11(5), 579-590. https://doi.org/10.5194/jbji-11-579-2026

Image Credits: AI Generated

DOI: 10.5194/jbji-11-579-2026

Keywords: vascularized fibular graft, infected non-union, fracture-related infection, limb salvage, bone consolidation, competing-risk analysis, osteomyelitis, microsurgery, bone grafting, amputation, biofilm infection, orthopedic surgery

Fracture-related infection, often abbreviated FRI, occurs when bacteria colonize the site of a broken bone, frequently around the plates, screws, or nails used to stabilize the fracture. The condition is estimated to affect roughly one to two percent of closed fractures, but the risk climbs dramatically in severe open injuries, exceeding thirty percent in Gustilo-Anderson type III open fractures depending on the anatomical site and injury severity. Treating these infections demands meticulously staged surgical protocols, prolonged hospitalization, and extended courses of antimicrobial therapy, all aimed simultaneously at eradicating the infection and restoring the biomechanical integrity of the skeleton. Reported eradication rates range widely, from twenty-nine to eighty-seven percent, and treatment failure can leave patients with irreversible functional compromise or even amputation.

The human toll of this complication extends well beyond the operating theatre. Traumatic injury alone can provoke adverse psychological outcomes, but the superimposition of a bone infection amplifies those effects through prolonged immobility, treatment uncertainty, and financially destabilizing periods of work incapacity. Infection recurrence portends intensified morbidity, extended therapy, and a profound deterioration in quality of life. Yet until now, the long-term effects of FRI on quality of life and mental health had remained murky, scattered across studies that used different instruments, definitions, and follow-up periods.

To bring order to this fragmented literature, the Regensburg team conducted a search compliant with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses, scanning PubMed, Web of Science, and Google Scholar for studies published between 2010 and August 2025. The initial search identified 7,808 articles, which the researchers whittled down through systematic screening to fifteen studies meeting strict inclusion criteria: adult patients with FRI, more than five participants, validated quality-of-life instruments, and a minimum follow-up of twelve months. Methodological quality was appraised using the Methodological Index for Non-Randomised Studies, known as MINORS, and risk of bias was assessed with the ROBINS-I framework, with discrepancies resolved through consensus meetings.

What the quality assessment revealed was a field built on shaky foundations. The evidence base was dominated by retrospective cohort studies, with no study achieving level I evidence, the gold standard of randomized trials. Studies achieved on average only 66.4 percent of the maximum MINORS score, and the average loss to follow-up was nearly twenty percent, ranging as high as 57.3 percent in one study. Ten of the fifteen studies carried a moderate risk of bias, three a high risk, and only two a low risk, with confounding identified as the principal source of bias because retrospective designs rarely fully account for factors that shape outcomes.

The quantitative findings nonetheless paint a coherent picture. In a meta-analysis of three studies covering 125 patients tracked before and after surgery, the physical component score of the SF-36 and SF-12 questionnaires rose by an average of 5.81 points at twelve months or more, an improvement that did not reach statistical significance. The mental component score rose by 3.86 points, also non-significant. More striking were the pooled long-term estimates drawn from seven studies comprising 262 patients: a mean physical component score of 38.9 and a mean mental component score of 51.2. When compared against normative data from the United States general population, where the mean physical score sits at 49.22, the FRI patients’ physical quality of life was significantly reduced, while the difference in mental quality of life was not statistically significant.

The psychological analysis added a troubling dimension. Three studies assessing 118 patients with the ICD-10-based Symptom Rating questionnaire, or ISR, found that the weighted mean depression score reached 1.08, crossing the cut-off value for a mild psychological symptom burden, a finding the researchers call caseness. The total ISR score of 0.68 also surpassed the caseness threshold, and sensitivity analyses confirmed that the depressive symptom finding was robust to the removal of any single study. Anxiety, compulsive, eating, and somatoform symptom scores, by contrast, remained below clinical thresholds, suggesting the psychological burden concentrates specifically in the depressive domain.

The authors are careful to caution against over-interpretation. Heterogeneity across the pooled studies was extreme, with the I-squared statistic reaching approximately 85.7 percent for the physical component score and a staggering 97.8 percent for the mental component score, indicating that study-specific, clinical, and methodological factors strongly influence observed outcomes. The pooled estimates, the researchers argue, should be read as descriptive reference benchmarks rather than precise predictions. Moreover, the depression findings cannot be attributed to infection itself, because the analysis lacked an appropriately matched control group of patients with comparable fractures, trauma exposure, or chronic conditions. It remains unclear whether the observed symptoms reflect the effects of the infection or the broader consequences of severe musculoskeletal injury and prolonged treatment.

Another complication is that the studies span more than fifteen years, a period during which the conceptual understanding and diagnostic framework of FRI evolved considerably. International consensus on a standardized definition of the condition emerged only recently, and earlier investigations often relied on less-standardized criteria, injecting further variability into the evidence base. Most cohorts also originated from German healthcare systems while the normative comparison data came from the United States, a mismatch the authors note is softened by previous work showing broad agreement between German and American SF-36 reference values, but which may still color the observed differences.

Perhaps the most clinically resonant insight emerges from the longitudinal data: successful eradication of infection does not inevitably restore patient-reported health. While two studies reported improved quality of life after treatment, the largest cohort actually demonstrated a decline following surgery, a discrepancy that underscores how the surgical battle against infection and the patient’s subjective recovery can diverge. The authors call for prospective, properly blinded studies using standardized FRI definitions, validated quality-of-life instruments, longitudinal follow-up, integrated psychological assessment, and carefully selected control groups to clarify whether the observed impairments arise primarily from the infection, the severe trauma, the surgical treatment, or the cumulative burden of recovery. In the meantime, they suggest, regular psychological screening of FRI patients deserves a place in routine follow-up care, because the wounds this complication leaves behind are not always visible on an X-ray.

Subject of Research: Long-term quality of life and depressive symptoms after fracture-related infection treatment

Article Title: Investigating long-term quality of life and depressive symptoms following fracture-related infection: a systematic review with meta-analysis of heterogeneous evidence

Article References: Betker, J. A., Walter, N., Rupp, M., Baertl, S., & Alt, V. (2026). Investigating long-term quality of life and depressive symptoms following fracture-related infection: a systematic review with meta-analysis of heterogeneous evidence. Journal of Bone and Joint Infection, 11(5), 569-577. https://doi.org/10.5194/jbji-11-569-2026

Image Credits: AI Generated

DOI: 10.5194/jbji-11-569-2026

Keywords: fracture-related infection, quality of life, depression, systematic review, meta-analysis, orthopaedic surgery, osteomyelitis, patient-reported outcomes, SF-36, mental health, trauma surgery, psychological screening

The clinical course began with what appeared to be a subungual hematoma, a collection of blood beneath the toenail of the kind familiar to anyone who has ever dropped a heavy object on a foot. Trephination, a procedure in which a small hole is made in the nail plate to relieve pressure and drain the trapped blood, was performed under the assumption that this was the problem. But two weeks after the procedure, the swelling had not resolved and the dark discoloration beneath the nail persisted. A clinical photograph taken at that point documented marked soft-tissue swelling of the toe along with the stubborn subungual discoloration, findings that prompted the team to look deeper. What the imaging revealed would rewrite the entire diagnostic picture.

A frontal radiograph of the toe demonstrated a destructive, predominantly lytic process replacing the entire distal phalanx, the small bone at the very tip of the great toe, in the region distal to the open physis, the growth plate that in children remains a cartilaginous zone between the bony shaft and the epiphysis. The normal trabecular architecture, the delicate internal lattice of bony struts that gives healthy bone its strength and appearance on X-ray, had been completely lost. In its place the radiologists described a pattern of bone destruction that was permeative to moth-eaten, terms that refer to the way aggressive lesions riddle bone with countless tiny, ill-defined holes rather than producing one clean cavity. Cortical thinning and disruption were also present, meaning the dense outer shell of the bone had been eroded and breached by the growing tumor.

Notably, the physeal contour remained intact. The growth plate, a structure that in growing children acts as a boundary between bone segments, had not yet been visibly breached by the process, even though the bone beyond it had been substantially destroyed. This detail matters because the behavior of tumors relative to the physis can offer clues about their nature and extent, and because preserving the physis has implications for surgical planning in a skeletally immature patient. Even with this anatomical nuance, the overall radiographic appearance was unmistakably aggressive. In pediatric bone radiology, permeative destruction with cortical breakdown is a red flag that demands consideration of malignancy, whatever the clinical history might suggest.

Given the boy’s history of repeated crush injuries, chronic osteomyelitis, a persistent infection of the bone, was the initial suspicion. This was a reasonable hypothesis. Chronic osteomyelitis can follow trauma, can produce lytic bone destruction, and is far more common than a malignant tumor in the distal phalanx of a toe. The distinction, however, could not be made on imaging alone, and biopsy was performed. The tissue diagnosis established Ewing sarcoma, a small round blue cell tumor driven in the vast majority of cases by a characteristic chromosomal translocation that fuses the EWSR1 gene with members of the ETS family of transcription factors, most commonly FLI1. This fusion protein acts as an aberrant transcriptional regulator, driving the uncontrolled proliferation that defines the disease. Definitive diagnosis of Ewing sarcoma typically rests on a combination of histology, immunohistochemistry demonstrating membrane staining for CD99, and molecular confirmation of the pathognomonic fusion.

The rarity of this presentation cannot be overstated. Ewing sarcoma is the second most common primary malignant bone tumor in children and adolescents, yet it has a strong predilection for specific locations: the pelvis, the femur, the tibia, the ribs, and the bones of the chest wall. It typically arises in the diaphysis or metaphysis of long bones, and involvement of the small bones of the hands and feet is exceptionally uncommon. Within those small bones, the distal phalanges are the rarest of sites. The authors of the report note that Ewing sarcoma of the toes is exceptionally rare, with distal phalangeal involvement reported in only a handful of cases worldwide. Every published instance therefore becomes a teaching case, because the accumulated experience of most radiologists and oncologists with tumors at this site is close to zero.

That rarity carries a real clinical cost, and it is the central message of the report: unusual location and clinical resemblance to trauma or infection may delay recognition. In this case, three months elapsed between the onset of symptoms and the establishment of the correct diagnosis, with the interval punctuated by procedures and treatments aimed at conditions the toe did not actually have. Delay in diagnosing Ewing sarcoma is not a trivial matter. The tumor is highly aggressive, with a capacity for local infiltration and early hematogenous metastasis, most commonly to the lungs and to other bones. Modern multimodal therapy, combining intensive multi-agent chemotherapy with local control through surgery, radiation, or both, has transformed five-year survival for localized disease, but outcomes deteriorate sharply once metastatic spread has occurred. Every week of diagnostic delay is a week in which a curable localized tumor has the opportunity to become something far worse.

The case also illustrates a broader principle in radiology and clinical medicine: the history is a guide, not a verdict. A plausible mechanism of injury, a swollen painful digit, and a dark nail can lull clinicians into anchoring on subungual hematoma and its complications, and later on osteomyelitis, without ever questioning whether the underlying process might be neoplastic. The authors urge radiologists to maintain suspicion for malignancy when confronted with aggressive phalangeal bone destruction, even when the clinical history suggests a more common process. In practical terms, this means that when an X-ray of a small bone shows permeative destruction, cortical disruption, and loss of trabecular architecture, the radiology report should explicitly flag the possibility of an aggressive neoplasm and recommend further evaluation, including magnetic resonance imaging to define the soft-tissue extent and marrow involvement, and ultimately biopsy to obtain tissue.

For the wider audience beyond the radiology reading room, the story is a reminder that persistent symptoms that fail to respond to appropriate treatment deserve escalation, not repetition. A crushed toe that keeps hurting and swelling for months, that darkens beneath the nail and does not improve after drainage, is not behaving like a simple injury. Children and adolescents are not immune to malignant bone tumors, and while the odds overwhelmingly favor benign explanations for a sore toe, the consequences of missing the rare alternative are profound. The authors of this report, who obtained informed consent from the patient’s parent for publication of the clinical information and images, have contributed a documented example of exactly this diagnostic trap, complete with the clinical photograph and radiograph that show how deceptive the presentation can be.

Ultimately, the case of the great toe distal phalanx joins a small but important body of literature documenting Ewing sarcoma in the most peripheral bones of the body. It underscores the value of open-access publication in pediatric radiology, allowing a single instructive case to reach clinicians everywhere who might otherwise never encounter this entity in their own practices. It reinforces the technical vocabulary of aggressive bone lesions, permeative and moth-eaten patterns, cortical disruption, and physeal relationships, as more than academic descriptors: they are the visual signatures that separate a tumor from an infection and from a healed crush injury. And above all, it demonstrates that in medicine, as in the imaging itself, what lies beneath the surface can only be known when someone thinks to look, and keeps looking when the first answer does not fit.

Subject of Research: Ewing sarcoma of the great toe distal phalanx in a pediatric patient

Article Title: Ewing sarcoma of the great toe distal phalanx

Article References: Thach, D., & Zarka, A. (2026). Ewing sarcoma of the great toe distal phalanx. Pediatric Radiology. https://doi.org/10.1007/s00247-026-06773-1

Image Credits: AI Generated

DOI: 10.1007/s00247-026-06773-1

Keywords: Ewing sarcoma, pediatric radiology, bone tumor, distal phalanx, great toe, lytic bone lesion, osteomyelitis, subungual hematoma, biopsy, radiography, sarcoma, diagnostic delay